The goal of this course is to explain how nurses can monitor and teach patients to safely use medications that selectively inhibit cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), first-line treatment for erectile dysfunction.
Course Publication Date:
May 19, 2020
This course is available with
NO ADDITIONAL FEE if you have an active
one year unlimited membership!
| Author: | Denise L. Gray RN, MAS, BSN, CCM |
| Course No: | SED010620 |
| Contact Hours: | 1.00 |
| Delivery Method: | Online Self Study |
| Category: | Community & Home Health
Emergency & Trauma Medicine
Geriatric Medicine
Medical & Surgical Issues
Psychiatric & Mental Health
|
|
|
|
Learning Objectives
Recognize examples of medications that selectively inhibit cGMP-specific phosphodiesterase type 5 (PDE5).
Identify possible drug interactions with cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors.
Describe how nurses can monitor patients for possible adverse drug events resulting from cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors.
Select information to teach patients taking cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors.